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Abstract
The objective of this study was to determine whether the interaction between type of serious 
mental illness (SMI) and pre-treatment drinking severity, assessed by ethyl glucuronide (EtG), 
predicts EtG-positive urine samples submitted during treatment in outpatients with co-occurring 
alcohol dependence and SMI. Seventy-nine participants were randomized to treatment-as-usual or 
treatment-as-usual and contingency management (CM) targeting alcohol abstinence. Generalized 
estimating equations were used to assess the interaction of pre-treatment drinking (heavy drinking 
or light drinking) and SMI diagnosis (major depression, bipolar, or schizophrenia-spectrum 
disorders) across a 12-week treatment period. In the overall sample, the interaction of drinking 
severity and SMI diagnosis (p = 0.006) was associated with alcohol abstinence. Exploratory 
analyses of the interaction term among participants randomized to CM (n = 40; p = 0.008) were 
associated with alcohol abstinence during CM. Type of SMI diagnosis was associated with 
treatment outcomes in individuals who engaged in heavy drinking, but not light drinking, prior to 
treatment.
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Nearly 50% of people with serious mental illness (SMI), defined as schizophrenia-spectrum, 
bipolar, and recurrent major depressive disorders experience a co-occurring alcohol use 
disorder in their lifetimes (Davis et al. 2008; Koskinen et al. 2009; Regier et al. 1990). These 
individuals have high levels of psychotic symptoms, inpatient psychiatric and emergency 
care utilization, treatment dropout, and suicide as a result of co-occurring disorders (Buckley 
and Brown 2006; Gonzalez et al. 2007; Kreyenbuhl et al. 2009; McGovern et al. 2007). 
Various behavioral treatments (e.g., cognitive behavior therapy, contingency management 
(CM)) or a combination of treatments are associated with reductions in alcohol and drug use 
in adults with SMI (Barrowclough et al. 2010; Bellack et al. 2006; Bradizza et al. 2014; 
McDonell et al. 2013, 2017). However, less is known about the predictors of treatment 
outcomes in those receiving co-occurring disorder treatment for alcohol and schizophrenia-
spectrum, bipolar I and II, or major depressive disorders.
CM provides reinforcers for targeted behavior, typically abstinence verified by urine drug 
tests, and is associated with decreased substance use, psychiatric symptoms, and 
hospitalization in outpatients diagnosed with an SMI (Bellack et al. 2006; McDonell et al. 
2013, 2017). In two randomized trials of CM, one targeting stimulant drug use and the other 
alcohol use, pre-treatment alcohol or drug positive urine tests were associated with poor 
treatment outcomes (Angelo et al. 2013). In a trial of CM targeting alcohol use, participants 
submitted urine samples that were tested for ethyl glucuronide (EtG), an alcohol metabolite, 
for 4 weeks before randomization. Participants who had pre-randomization EtG levels 
consistent with regular heavy drinking (EtG > 499 ng/mL) attained a period of alcohol 
abstinence during CM that was 2.5 times shorter than those who were light drinkers 
(McDonell et al. 2017).
Findings have been inconsistent in terms of the association between type of SMI diagnosis 
and treatment outcomes. We observed that higher levels of psychological distress (e.g., 
anxiety, stress), rather than type of SMI diagnosis was a predictor of abstinence among 
adults with SMI receiving CM for stimulant use (Angelo et al. 2013). In non-SMI 
populations, depressive symptoms were associated with poorer treatment outcomes in CM 
for cocaine dependence (García-Fernández et al. 2013). Another study found that the 
diagnosis of major depression or antisocial personality disorder predicted poorer treatment 
outcomes at 1-year follow-up among adults in drug treatment (Compton et al. 2003).
Pre-treatment substance use and psychiatric symptom severity have been independently 
associated with treatment outcomes in CM, and initial evidence suggests that type of 
psychiatric diagnosis is associated with addiction treatment outcomes. However, to our 
knowledge no research has tested whether the interaction of these variables predicts 
addiction treatment outcomes. Understanding how the heterogeneity in alcohol use and SMI 
diagnosis interact could provide clinicians with valuable information to improve and tailor 
treatment for subgroups of adults with co-occurring disorders. The purpose of this study was 
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to explore whether the interaction of pre-treatment drinking severity (heavy versus light 
drinking) assessed by EtG and type of SMI diagnosis (major depression, bipolar, or 
schizophrenia-spectrum disorders) predicted alcohol abstinence in the overall sample of 
adults with SMI and AUDs receiving treatment-as-usual (TAU; N = 79), as well as in those 
randomized to CM (n = 40).
Methods
Sample
Participants were recruited from multiple community mental health and substance use 
treatment agencies in Washington State. Seventy-nine adults who met criteria for the 
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision 
(DSM-IV-TR) diagnoses of alcohol dependence and co-occurring schizophrenia-spectrum (n 
= 29), bipolar (n = 24), or major depressive disorders (n = 27), assessed by the Mini 
International Neuro-psychiatric Interview (M.I.N.I) were enrolled (Sheehan et al. 1998). 
Other inclusion criteria (detailed in McDonell et al. 2017) included alcohol use on 5 out of 
the prior 30 days. The mean age of participants was 45.38 (SD = 10.20) years, and 65% (n = 
51) were male, 53% (n = 42) were white, 29% (n = 23) black, 15% (n = 12) other, and 3% (n 
= 2) of unknown racial identify. Fifty-three percent (n = 42) were heavy drinkers as defined 
by pre-treatment EtG levels. Participants provided written informed consent and the study 
was approved by the University of Washington’s Institutional Review Board.
Study Design and Procedures
McDonell et al. (2017) conducted a 16-week randomized controlled trial of CM for alcohol 
dependence (clinicaltrials.govidentifier:NCT01567943). Participants engaged in a 4-week 
induction period (weeks 1–4), developed to increase study retention after randomization that 
included treatment-as-usual(TAU). Participants received reinforcers (prize draws) three 
times a week for submitting urine samples regardless of whether it was positive or negative 
and for alcohol and provided self-reported data on alcohol use. After the induction period, 
participants who provided at least one EtG-positive urine sample continued to receive TAU 
and were randomized (weeks 5–16) to either the CM (n = 40) or non-contingent (NC; n = 
39) control conditions for the 12-week treatment period. Following the treatment period, 
participants completed a 3-month follow-up (weeks 17–28) period.
Study Interventions
TAU occurred at three sites of a large urban community mental health center in Seattle, WA. 
Addiction treatment consisted of group counseling sessions 2–4 times a week. Additional 
services were provided by site staff, including individual addiction counseling, case 
management, medication management, and housing support.
The variable magnitude of reinforcement procedure was utilized and involved “prize draws” 
from a bucket that contained tokens that reflected various values. Fifty percent of the tokens 
read “good job,” 41.8% read “small” ($1 value), 8.0% read “large” ($20 value), and 0.2% 
read “jumbo” ($80 value). NC control participants earned at least three prize draws per urine 
sample submitted regardless of results, and CM participants earned prize draws for each 
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EtG-negative sample submitted and an additional draw for each consecutive week of 
abstinence. EtG-positive urine tests resulted in no prize draws and a reset to three prize 
draws the next time an EtG-negative sample was provided. CM participants also received 
gift cards if they attended some ($5) or all ($10) of their addiction treatment groups each 
week. NC control participants received the average value of gift cards received by the CM 
condition regardless of addiction treatment group attendance.
Measures
Participants completed an enrollment interview that included the M.I.N.I., which was used to 
determine type of SMI diagnosis and assess for alcohol dependence and drug use disorders. 
M.I.N.I. major depressive episode, manic episode, psychotic disorders, and drug and alcohol 
dependence/abuse diagnostic sections were administered by trained research staff. Urine 
samples were collected at each study visit and assessed for EtG using Diagnostic Reagents 
Incorporated EtG-immunoassay onsite with a Thermo Fisher Indiko analyzer (Fremont, 
CA), with a detectable range of 0 to 2000 ng/mL. Mean EtG levels were calculated across 
the 4-week induction period for each participant to determine pre-treatment drinking 
severity, those with EtG >499ng/mL (i.e., heavy drinking) or EtG <500 ng/mL (i.e., light 
drinking) (McDonell et al. 2015). The outcome variable was number of EtG-positive (EtG > 
149 ng/mL) urine samples submitted during the 36-visit treatment period.
Data Analysis
Generalized estimating equation (GEE) analyses were used to assess the relationship 
variables of interest and alcohol use during the 12-week treatment period. The first model (N 
= 79) controlled for treatment condition, SMI diagnosis (schizophrenia-spectrum, bipolar, 
major depressive disorders), pre-treatment drinking severity, and the interaction between 
type of SMI diagnosis and pre-treatment drinking severity with the outcome being EtG-
positive urine samples during treatment (1 = yes, 0 = no). The second model within the CM 
condition only (n = 40) assessed whether the interaction of pre-treatment drinking severity 
and SMI diagnosis was associated with EtG-positive urine samples, controlling for pre-
treatment drinking severity and SMI diagnosis. In both analyses, all possible pairwise 
comparisons were conducted on the interaction term utilizing Bonferroni correction to avoid 
inflation of the alpha rate. Odds ratios (OR) were reported, 95% confidence intervals (CI), 
and significance was set at p < 0.05. Analyses were performed using IBM SPSS 24.0 and 
post hoc tests were conducted in Stata 12.0 (StataCorp, College Station, TX).
Results
Across the entire sample, after controlling for treatment conditions (χ2 (1) = 7.86, p = 
0.005), pre-treatment drinking severity (χ2 (1) = 38.55, p = 0.001), and SMI diagnosis (χ2 
(2) = 7.64, p = 0.022), the interaction of pre-treatment drinking severity and SMI diagnosis 
(χ2 (2) = 10.39, p = 0.006) was a significant predictor of submitting EtG-positive urine 
samples during the treatment period.
Post hoc tests for the interaction term revealed that heavy drinkers with bipolar disorders 
(OR = 0.09, 95% CI 0.04–0.22) and schizophrenia-spectrum disorders (OR = 0.25, 95% CI 
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0.11–0.58) were less likely than heavy drinkers with major depression to submit EtG-
positive urine samples during the treatment period. Heavy drinkers with schizophrenia-
spectrum disorders were 2.83 times (95% CI 1.32–6.09) more likely than heavy drinkers 
with bipolar disorder to submit EtG-positive urine samples during the treatment period (see 
Fig. 1). No significant differences were found among light drinkers across SMI diagnoses. 
Although, among those with major depression (OR = 29.28, 95% CI 10.53–81.45) and 
schizophrenia-spectrum (OR = 5.62, 95% CI 2.37–13.35) disorders, heavy drinkers were 
more likely than light drinkers to submit EtG-positive samples during treatment. Differences 
between heavy and light drinkers in those with bipolar were not significant.
Similar findings were observed when analyses were conducted on participants randomized 
to CM only. After controlling for pre-treatment drinking severity (χ2 (1) = 23.41, p = 0.001) 
and SMI diagnosis (χ2 (2) = 2.07, p = 0.36), the interaction of pre-treatment drinking 
severity and SMI diagnosis (χ2 (2) = 9.72, p = 0.008) was associated with EtG-positive 
urine samples during the treatment period. Bonferroni post hoc tests, conducted on the 
interaction term revealed that heavy drinkers with bipolar (OR = 0.13, 95% CI 0.03–0.47) 
and schizophrenia-spectrum (OR = 0.13, 95% CI 0.03–0.47) disorders were less likely than 
heavy drinkers with major depression to submit EtG-positive urine samples during the 
treatment period. No significant differences were found among light drinkers across SMI 
diagnoses. However, among those with major depression (OR = 87.02, 95% CI 17.08–
443.23) and schizophrenia-spectrum (OR = 5.57, 95% CI 1.52–20.45) disorders, heavy 
drinkers were more likely than light drinkers to submit EtG-positive samples during 
treatment. Differences between heavy and light drinkers in those with bipolar were not 
significant.
Discussion
Previous findings have suggested that light drinkers relative to heavy drinkers were 
significantly less likely to submit EtG-positive urine samples during the treatment period 
and that psychiatric distress rather than SMI diagnosis predicted outcomes (Angelo et al. 
2013; McDonell et al. 2017). Although not a CM trial, research has revealed that individuals 
with a major depression diagnosis were more likely to meet criteria for alcohol dependence 
compared to other psychiatric disorders(Compton et al. 2003). Contrary to previous research 
that found psychiatric distress not SMI was a significant predictor of outcomes, our study 
found that alcohol use during the treatment period varied by SMI diagnosis in heavy, but not 
light drinkers, as seen in Fig. 1. Heavy drinkers with major depression were more likely to 
submit EtG-positive urine samples during treatment compared to heavy drinkers with bipolar 
and schizophrenia-spectrum disorders. Similar results were also found when analyses were 
restricted to the CM condition only. In contrast, outcomes did not differ across SMI 
diagnoses in light drinkers.
Results suggest that the heterogeneity of both alcohol use and psychiatric diagnosis are 
important predictors of treatment out comes in adults with co-occurring disorders. While a 
number of frameworks for conceptualizing heterogeneity of substance use and psychiatric 
disorders have been proposed (McGovern et al. 2007; Ries 1993), our findings suggest that 
simple tools, such as urine tests for EtG and psychiatric diagnosis, can be used to identify 
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who is likely to respond to TAU and CM. The implications from this study in addition to 
findings from our other study (Oluwoye et al., Under Review) examining the differences in 
treatment outcomes among individuals with stimulant use disorders and various SMIs (i.e., 
schizophrenia, bipolar, and major depressive disorders) suggest that personalized treatment 
approaches should be tailored to specific SMI diagnosis and substance use severity among 
adults with co-occurring disorders.
The relatively small sample size of this study, particularly when analyzing outcomes in the 
CM group, resulted in small numbers of individuals in specific groups (e.g., light drinkers 
with depression). Therefore, it is possible that outliers may have influenced results. 
Participant recruitment from one treatment facility may also limit the generalizability of 
study findings. Replication of our findings in a larger sample recruited across multiple 
agencies is needed. While it is possible that diagnostic errors could have occurred, we used a 
structured diagnostic interview and other procedures including the use of trained research 
staff to assure accuracy of diagnosis.
Conclusions
Findings provide initial evidence that the interaction between drinking severity and 
psychiatric diagnosis, rather than the effect of each of these variables in isolation, is 
important when predicting alcohol treatment response in those who suffer from co-occurring 
disorders. If validated in larger samples, this finding may have important implications for 
improving outcomes of heavy drinkers, especially those who suffer from co-occurring major 
depression.
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Mean percentage of ethyl glucuronide (EtG)-positive urine samples during treatment across 
heavy and light drinkers and serious mental illness diagnoses (N = 79). Note: EtG, ethyl 
glucuronide; significance of main effects: pre-treatment drinking severity (p = 0.001) and 
SMI diagnosis (p = 0.022)
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